← Back to patent-cliff list
Nesuparib
Tier C — Watch / tradeNesuparib
Jeil Pharmaceutical Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PARP, TNKS
Indications (approved)：Gastric cancer, Ovarian cancer, Pancreatic cancer, Female reproductive system cancer, Endometrial cancer, 胰腺导管癌, Solid tumour
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Nesuparib?
Approved indications include: Gastric cancer, Ovarian cancer, Pancreatic cancer, Female reproductive system cancer, Endometrial cancer, 胰腺导管癌, Solid tumour.
When does the Nesuparib patent expire?
No public expiry year is available for Nesuparib yet; this page updates once verified.
How do I get a quote for Nesuparib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05